Literature DB >> 25608795

FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.

Changhua Zhuo1, Ye Xu, Mingang Ying, Qingguo Li, Liyong Huang, Dawei Li, Sanjun Cai, Bin Li.   

Abstract

The tumor microenvironment composites a mixture of immune lymphoid cells, myeloid cells, stromal cells with complex cytokines, as well as numerous lymphovascular vessels. Colorectal cancer (CRC) is a common malignancy and one of the leading causes of tumor-related death in the United States and worldwide. The immune status in the tumor microenvironment contributes to the survival of a patient with CRC. Regulatory T cells (Tregs) are considered a key factor in immune escape and immunotherapy failure among cancer patients. The transcription factor forkhead box P3 (FOXP3) is a crucial intracellular marker and also a key developmental and functional factor for CD4+CD25+ Tregs. Tregs are correlated with survival in various human neoplasms, and elevated proportions of Tregs are usually associated with unfavorable clinical outcomes. However, the role of Tregs in CRC remains controversial. High densities of tumor-infiltrating Tregs in CRC patients are reported to be correlated with worse or better outcomes. And Tregs may not be predictive of prognosis after resection of the primary tumor. The exact explanations for these discordant results remain unclear. The heterogeneous instincts of cell phenotype, gene expression, and functional activities of Tregs may partly contribute this contrasting result. Furthermore, the lack of a robust marker for identifying Tregs or due to the different techniques applied is also account. The Treg-specific demethylated region (TSDR) was recently reported to be a specific epigenetic marker for natural Tregs (nTregs), which can stably express FOXP3. The FOXP3-TSDR demethylation assay may be an promising technique for CRC-related nTregs studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25608795     DOI: 10.1007/s12026-014-8616-y

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  126 in total

1.  T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development.

Authors:  Naganari Ohkura; Masahide Hamaguchi; Hiromasa Morikawa; Kyoko Sugimura; Atsushi Tanaka; Yoshinaga Ito; Motonao Osaki; Yoshiaki Tanaka; Riu Yamashita; Naoko Nakano; Jochen Huehn; Hans Joerg Fehling; Tim Sparwasser; Kenta Nakai; Shimon Sakaguchi
Journal:  Immunity       Date:  2012-11-01       Impact factor: 31.745

2.  Cell interactions in the induction of tolerance: the role of thymic lymphocytes.

Authors:  R K Gershon; K Kondo
Journal:  Immunology       Date:  1970-05       Impact factor: 7.397

Review 3.  Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation.

Authors:  Ana Izcue; Janine L Coombes; Fiona Powrie
Journal:  Immunol Rev       Date:  2006-08       Impact factor: 12.988

4.  CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice.

Authors:  Susan E Erdman; Jane J Sohn; Varada P Rao; Prashant R Nambiar; Zhongming Ge; James G Fox; David B Schauer
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

5.  Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death.

Authors:  Benedikt Fritzsching; Nina Oberle; Eva Pauly; Robert Geffers; Jan Buer; Johannes Poschl; Peter Krammer; Otwin Linderkamp; Elisabeth Suri-Payer
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

6.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

7.  Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.

Authors:  Hiroyuki Suzuki; Nobuhito Chikazawa; Takehiko Tasaka; Junji Wada; Akio Yamasaki; Yoshiki Kitaura; Masae Sozaki; Masao Tanaka; Hideya Onishi; Takashi Morisaki; Mitsuo Katano
Journal:  Cancer Immunol Immunother       Date:  2009-11-12       Impact factor: 6.968

8.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

9.  Demethylation analysis of the FOXP3 locus shows quantitative defects of regulatory T cells in IPEX-like syndrome.

Authors:  F Barzaghi; L Passerini; E Gambineri; S Ciullini Mannurita; T Cornu; E S Kang; Y H Choe; C Cancrini; S Corrente; R Ciccocioppo; M Cecconi; G Zuin; V Discepolo; C Sartirana; J Schmidtko; A Ikinciogullari; A Ambrosi; M G Roncarolo; S Olek; R Bacchetta
Journal:  J Autoimmun       Date:  2012-01-20       Impact factor: 7.094

10.  TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.

Authors:  Liang Zhou; Jared E Lopes; Mark M W Chong; Ivaylo I Ivanov; Roy Min; Gabriel D Victora; Yuelei Shen; Jianguang Du; Yuri P Rubtsov; Alexander Y Rudensky; Steven F Ziegler; Dan R Littman
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

View more
  30 in total

1.  Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status.

Authors:  Ji Ae Lee; Seung-Yeon Yoo; Hyeon Jeong Oh; Seorin Jeong; Nam-Yun Cho; Gyeong Hoon Kang; Jung Ho Kim
Journal:  Cancer Immunol Immunother       Date:  2020-07-04       Impact factor: 6.968

2.  Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer.

Authors:  Min-Chao Duan; Wei Han; Pei-Wen Jin; Yu-Ping Wei; Qiu Wei; Liang-Ming Zhang; Jun-Chen Li
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

Review 3.  The case for immune-based approaches in biliary tract carcinoma.

Authors:  Austin G Duffy; Oxana V Makarova-Rusher; Tim F Greten
Journal:  Hepatology       Date:  2016-06-18       Impact factor: 17.425

Review 4.  T cell metabolic fitness in antitumor immunity.

Authors:  Peter J Siska; Jeffrey C Rathmell
Journal:  Trends Immunol       Date:  2015-03-12       Impact factor: 16.687

5.  Intratumoral density of regulatory T cells is a predictor of host immune response and chemotherapy response in colorectal cancer.

Authors:  Masanori Oshi; Joy Sarkar; Rongrong Wu; Yoshihisa Tokumaru; Li Yan; Kazuya Nakagawa; Atsushi Ishibe; Ryusei Matsuyama; Itaru Endo; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

6.  Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation.

Authors:  Julie Jacobs; Vanessa Deschoolmeester; Karen Zwaenepoel; Tal Flieswasser; Christophe Deben; Jolien Van den Bossche; Christophe Hermans; Christian Rolfo; Marc Peeters; Olivier De Wever; Filip Lardon; Vasiliki Siozopoulou; Evelien Smits; Patrick Pauwels
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

7.  Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer.

Authors:  Baodan Yu; Junli Wang; Chen He; Wei Wang; Jianli Tang; Runhui Zheng; Chengzhi Zhou; Huanhuan Zhang; Zhiping Fu; Qiasheng Li; Jun Xu
Journal:  Exp Ther Med       Date:  2017-06-08       Impact factor: 2.447

8.  Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis.

Authors:  Veronica De Simone; Giulia Ronchetti; Eleonora Franzè; Alfredo Colantoni; Angela Ortenzi; Massimo C Fantini; Angelamaria Rizzo; Giuseppe S Sica; Pierpaolo Sileri; Piero Rossi; Thomas T MacDonald; Francesco Pallone; Giovanni Monteleone; Carmine Stolfi
Journal:  Oncotarget       Date:  2015-04-30

Review 9.  Treg: A Promising Immunotherapeutic Target in Oral Diseases.

Authors:  Yujing Zhang; Jihua Guo; Rong Jia
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

10.  Genetic Variants in the Regulatory T cell-Related Pathway and Colorectal Cancer Prognosis.

Authors:  Sonja Neumeyer; Xinwei Hua; Petra Seibold; Lina Jansen; Axel Benner; Barbara Burwinkel; Niels Halama; Sonja I Berndt; Amanda I Phipps; Lori C Sakoda; Robert E Schoen; Martha L Slattery; Andrew T Chan; Manish Gala; Amit D Joshi; Shuji Ogino; Mingyang Song; Esther Herpel; Hendrik Bläker; Matthias Kloor; Dominique Scherer; Alexis Ulrich; Cornelia M Ulrich; Aung K Win; Jane C Figueiredo; John L Hopper; Finlay Macrae; Roger L Milne; Graham G Giles; Daniel D Buchanan; Ulrike Peters; Michael Hoffmeister; Hermann Brenner; Polly A Newcomb; Jenny Chang-Claude
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-02       Impact factor: 4.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.